Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives $20.40 Average PT from Analysts

Contineum Therapeutics, Inc. (NASDAQ:CTNM) has been assigned a consensus rating of “Moderate Buy” from the eight brokerages that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $19.00.

A number of research firms have weighed in on CTNM. Wall Street Zen cut Contineum Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Robert W. Baird dropped their price objective on Contineum Therapeutics from $16.00 to $14.00 and set an “outperform” rating on the stock in a report on Monday, November 24th. Royal Bank Of Canada cut their target price on Contineum Therapeutics from $25.00 to $22.00 and set an “outperform” rating on the stock in a research report on Friday, November 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Contineum Therapeutics in a report on Wednesday, October 8th. Finally, Leerink Partners assumed coverage on shares of Contineum Therapeutics in a report on Thursday, November 13th. They set an “outperform” rating and a $22.00 price objective on the stock.

Contineum Therapeutics Stock Up 1.5%

Shares of NASDAQ:CTNM opened at $9.31 on Tuesday. Contineum Therapeutics has a fifty-two week low of $3.35 and a fifty-two week high of $13.57. The firm’s 50 day moving average price is $11.24 and its 200 day moving average price is $9.59. The stock has a market cap of $271.67 million, a price-to-earnings ratio of -4.14 and a beta of 1.21.

Contineum Therapeutics (NASDAQ:CTNM) last announced its quarterly earnings data on Thursday, October 30th. The company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.13. On average, equities analysts anticipate that Contineum Therapeutics will post -2.01 EPS for the current year.

Hedge Funds Weigh In On Contineum Therapeutics

Large investors have recently bought and sold shares of the stock. Strs Ohio purchased a new position in shares of Contineum Therapeutics during the first quarter worth about $27,000. Qube Research & Technologies Ltd purchased a new position in Contineum Therapeutics during the 2nd quarter worth approximately $43,000. Marex Group plc acquired a new position in Contineum Therapeutics during the second quarter worth approximately $45,000. Bridgeway Capital Management LLC purchased a new stake in Contineum Therapeutics in the second quarter valued at approximately $76,000. Finally, Jane Street Group LLC acquired a new stake in shares of Contineum Therapeutics in the second quarter valued at approximately $81,000.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.